Emyria Limited Receives Further Positive MDMA Analogue Screening Results
associated with unwanted clinical side effects. These positive results bring the total count of successfully screened MDMA analogues to date to 83 out of 85. Additional preclinical screening is now being planned with a leading CRO who will perform a number of assays to evaluate the solubility, partition coefficients and metabolic stability of each compound. These assays can help to predict absorption and brain uptake rates and
help identify compounds that are similar to MDMA in potency but with faster onset and shorter half-lives, which may be more suitable for clinical applications. Leading MDMA analogues will undergo more sophisticated pharmacokinetic studies, which
is important in helping select compounds for further in vivo efficacy studies.